In a new study for the research of asthma relief, a potential treatment has come to the attention of the National Institute for Health Research (NIHR) in London.
The study concerns the effects of an antibody, Omalizumab, on patients with asthma. Instead of traditional treatments for asthma that utilize steroids -- some of which are not helpful to asthmatic individuals -- Omalizumab is different. It acts by providing a longer period of relief from symptoms, which is crucial for the five million individuals in the U.K. who are being treated for the condition.
Novartis has come alongside the study, in the hopes of assisting.
"It is great news that Novartis has teamed up with the NIHR’s expert researchers to ensure that the right treatment is given to the right patient at the right time," Life Science Minister George Freeman said.
The NIHR seeks to identify the biomarkers affected by the use of the medication because understanding this could lead to more efficient treatment of asthma sufferers.
The study will be carried out in 14 research centers, running trials with 200 patients. The results of this study have the potential to aid individuals struggling with asthma by changing the way they receive treatment.